Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| IDEXX LABORATORIES INC /DEIDXX · Entity 3057 | EVP, CFO and Treasurer | August 20, 2026 | August 24, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
IDEXX LABORATORIES INC /DE
Report date August 20, 2026 · Filed August 24, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 4,507.444 |
Reported balance
After 2026-08-20 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-08-20 · Exercise / conversion · Acquired 265 · Balance 4,507.444 F1: Includes a total of 20 shares purchased under the Issuer Employee Stock Purchase Plan on March 31, 2026 and June 30, 2026. |
| Common StockSEC Table I · non-derivative | Direct | 4,421.444 |
Reported balance
After 2026-08-20 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-08-20 · Tax withholding · Disposed 86 · Balance 4,421.444 |
| Incentive Stock Option (right-to-buy)SEC Table II · derivative / convertible security · Conversion / exercise price $178.26 · Expires 2028-02-13 | Direct | 925 |
Reported balance
After 2026-08-20 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-08-20 · Exercise / conversion · Disposed 265 · Balance 925 F3: Not applicable F2: Grant of option to buy 1,190 shares of Issuer common stock that became exercisable in one installment on February 14, 2023. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes a total of 20 shares purchased under the Issuer Employee Stock Purchase Plan on March 31, 2026 and June 30, 2026.
F2: Grant of option to buy 1,190 shares of Issuer common stock that became exercisable in one installment on February 14, 2023.
F3: Not applicable
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 20, 2026 Filed Aug 24, 2026 21:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionIncentive Stock Option (right-to-buy) · Derivative | 265 | Not disclosed Strike: $178.26 | Not disclosed |
DisclosureSEC source: 0000874716-26-000125 · wk-form4_1787605205.xml · derivative · entry 3 Emerson Andrew · CIK 0002058587 · EVP, CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 925 Underlying: Common Stock · 265 shares Expires 2028-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Not applicable F2 · derivative.exercise_date: Grant of option to buy 1,190 shares of Issuer common stock that became exercisable in one installment on February 14, 2023. Read SEC document |
| August 20, 2026 Filed Aug 24, 2026 21:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Tax withholdingCommon Stock | 86 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-26-000125 · wk-form4_1787605205.xml · nonDerivative · entry 2 Emerson Andrew · CIK 0002058587 · EVP, CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,421.444 Read SEC document |
| August 20, 2026 Filed Aug 24, 2026 21:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 265 | $178.26 | $47,238.90 |
DisclosureSEC source: 0000874716-26-000125 · wk-form4_1787605205.xml · nonDerivative · entry 1 Emerson Andrew · CIK 0002058587 · EVP, CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,507.444 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes a total of 20 shares purchased under the Issuer Employee Stock Purchase Plan on March 31, 2026 and June 30, 2026. Read SEC document |
| February 14, 2026 Filed Feb 18, 2026 00:30 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 194 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-26-000018 · wk-form4_1771374607.xml · derivative · entry 15 Emerson Andrew · CIK 0002058587 · EVP, CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 581 Underlying: Common Stock · 194 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F13 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments beginning on February 14, 2026. F13 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments beginning on February 14, 2026. F13 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments beginning on February 14, 2026. Read SEC document |
| February 14, 2026 Filed Feb 18, 2026 00:30 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 42 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-26-000018 · wk-form4_1771374607.xml · derivative · entry 14 Emerson Andrew · CIK 0002058587 · EVP, CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 83 Underlying: Common Stock · 42 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F12 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments beginning on February 14, 2025. F12 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments beginning on February 14, 2025. F12 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments beginning on February 14, 2025. Read SEC document |
| February 14, 2026 Filed Feb 18, 2026 00:30 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 94 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-26-000018 · wk-form4_1771374607.xml · derivative · entry 13 Emerson Andrew · CIK 0002058587 · EVP, CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 93 Underlying: Common Stock · 94 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F11 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments beginning on February 14, 2024. F11 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments beginning on February 14, 2024. F11 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments beginning on February 14, 2024. Read SEC document |
| February 14, 2026 Filed Feb 18, 2026 00:30 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 61 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-26-000018 · wk-form4_1771374607.xml · derivative · entry 12 Emerson Andrew · CIK 0002058587 · EVP, CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 61 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · derivative.exercise_price: Represents RSUs that were granted on February 14, 2025 and deferred in accordance with the Issuer's Deferred Compensation Plan and represents a contingent right to receive one share of Issuer common stock vesting in four annual installments, beginning February 14, 2026. Upon vesting, each such RSU will be recorded in an account under such Plan. F10 · derivative.exercise_date: Represents RSUs that were granted on February 14, 2025 and deferred in accordance with the Issuer's Deferred Compensation Plan and represents a contingent right to receive one share of Issuer common stock vesting in four annual installments, beginning February 14, 2026. Upon vesting, each such RSU will be recorded in an account under such Plan. F10 · derivative.expiration_date: Represents RSUs that were granted on February 14, 2025 and deferred in accordance with the Issuer's Deferred Compensation Plan and represents a contingent right to receive one share of Issuer common stock vesting in four annual installments, beginning February 14, 2026. Upon vesting, each such RSU will be recorded in an account under such Plan. Read SEC document |
| February 14, 2026 Filed Feb 18, 2026 00:30 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Tax withholdingCommon Stock | 123 | $629.35 | $77,410.05 |
DisclosureSEC source: 0000874716-26-000018 · wk-form4_1771374607.xml · nonDerivative · entry 6 Emerson Andrew · CIK 0002058587 · EVP, CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,222.444 F3 · price: Closing price of Issuer common stock on Nasdaq Global Select Market on February 13, 2026. F4 · balance_after: Includes 65 vested but deferred RSUs. Read SEC document |
| February 14, 2026 Filed Feb 18, 2026 00:30 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 65 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-26-000018 · wk-form4_1771374607.xml · nonDerivative · entry 5 Emerson Andrew · CIK 0002058587 · EVP, CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,345.444 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · shares: Represents Restricted Stock Units ('RSU') that were granted on February 14, 2025, were deferred in accordance with the Issuer's Deferred Compensation Plan and have vested. Upon vesting, these RSUs were recorded in an account under such Plan and represents a contingent right to receive one share of Issuer common stock that is payable as soon as practicable after the reporting person's separation of service with the Issuer or a date specified by the reporting person. Read SEC document |
| February 14, 2026 Filed Feb 18, 2026 00:30 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 194 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-26-000018 · wk-form4_1771374607.xml · nonDerivative · entry 4 Emerson Andrew · CIK 0002058587 · EVP, CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,280.444 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2026 Filed Feb 18, 2026 00:30 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 42 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-26-000018 · wk-form4_1771374607.xml · nonDerivative · entry 3 Emerson Andrew · CIK 0002058587 · EVP, CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,086.444 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2026 Filed Feb 18, 2026 00:30 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 94 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-26-000018 · wk-form4_1771374607.xml · nonDerivative · entry 2 Emerson Andrew · CIK 0002058587 · EVP, CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,044.444 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2026 Filed Feb 18, 2026 00:30 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 61 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-26-000018 · wk-form4_1771374607.xml · nonDerivative · entry 1 Emerson Andrew · CIK 0002058587 · EVP, CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,950.444 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes a total of 18.666 shares purchased under the Issuer Employee Stock Purchase Plan on September 30, 2025 and December 31, 2025. Read SEC document |
| February 12, 2026 Filed Feb 18, 2026 00:30 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 65 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-26-000018 · wk-form4_1771374607.xml · derivative · entry 11 Emerson Andrew · CIK 0002058587 · EVP, CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 193 Underlying: Common Stock · 65 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_price: Represents RSUs that were granted on February 14, 2025 and deferred in accordance with the Issuer's Deferred Compensation Plan and represents a contingent right to receive one share of Issuer common stock vesting in four annual installments, beginning February 14, 2026. Upon vesting, each such RSU will be recorded in an account under such Plan. F9 · derivative.exercise_date: Represents RSUs that were granted on February 14, 2025 and deferred in accordance with the Issuer's Deferred Compensation Plan and represents a contingent right to receive one share of Issuer common stock vesting in four annual installments, beginning February 14, 2026. Upon vesting, each such RSU will be recorded in an account under such Plan. F9 · derivative.expiration_date: Represents RSUs that were granted on February 14, 2025 and deferred in accordance with the Issuer's Deferred Compensation Plan and represents a contingent right to receive one share of Issuer common stock vesting in four annual installments, beginning February 14, 2026. Upon vesting, each such RSU will be recorded in an account under such Plan. Read SEC document |
| February 12, 2026 Filed Feb 18, 2026 00:30 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantRestricted Stock Unit · Derivative | 284 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-26-000018 · wk-form4_1771374607.xml · derivative · entry 10 Emerson Andrew · CIK 0002058587 · EVP, CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 284 Underlying: Common Stock · 284 shares Expires not disclosed F8 · derivative.exercise_price: Grant of RSUs that upon vesting, will be deferred and recorded in an account under the Issuer's Deferred Compensation Plan. This RSU grant vests in four annual installments, beginning February 14, 2027. F8 · derivative.exercise_date: Grant of RSUs that upon vesting, will be deferred and recorded in an account under the Issuer's Deferred Compensation Plan. This RSU grant vests in four annual installments, beginning February 14, 2027. F8 · derivative.expiration_date: Grant of RSUs that upon vesting, will be deferred and recorded in an account under the Issuer's Deferred Compensation Plan. This RSU grant vests in four annual installments, beginning February 14, 2027. Read SEC document |
| February 12, 2026 Filed Feb 18, 2026 00:30 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantRestricted Stock Unit · Derivative | 729 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-26-000018 · wk-form4_1771374607.xml · derivative · entry 9 Emerson Andrew · CIK 0002058587 · EVP, CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 729 Underlying: Common Stock · 729 shares Expires not disclosed F7 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock that vests in four annual installments, beginning February 14, 2027. F7 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock that vests in four annual installments, beginning February 14, 2027. F7 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock that vests in four annual installments, beginning February 14, 2027. Read SEC document |
| February 12, 2026 Filed Feb 18, 2026 00:30 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantIncentive Stock Option (right-to-buy) · Derivative | 162 | $0.00 Strike: $617.20 | $0.00 |
DisclosureSEC source: 0000874716-26-000018 · wk-form4_1771374607.xml · derivative · entry 8 Emerson Andrew · CIK 0002058587 · EVP, CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 162 Underlying: Common Stock · 162 shares Expires 2036-02-11 F6 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that becomes exercisable in one installment on February 14, 2030. Read SEC document |
| February 12, 2026 Filed Feb 18, 2026 00:30 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantNon-Qualified Stock Option (right-to-buy) · Derivative | 4,270 | $0.00 Strike: $617.20 | $0.00 |
DisclosureSEC source: 0000874716-26-000018 · wk-form4_1771374607.xml · derivative · entry 7 Emerson Andrew · CIK 0002058587 · EVP, CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,270 Underlying: Common Stock · 4,270 shares Expires 2036-02-11 F5 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that becomes exercisable in four annual installments beginning February 14, 2027. Read SEC document |
| August 07, 2025 Filed Aug 11, 2025 22:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionIncentive Stock Option (right-to-buy) · Derivative | 1,849 | Not disclosed Strike: $141.60 | Not disclosed |
DisclosureSEC source: 0000874716-25-000129 · wk-form4_1754949616.xml · derivative · entry 3 Emerson Andrew · CIK 0002058587 · EVP, CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,849 shares Expires 2027-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Not applicable. F2 · derivative.exercise_date: Grant of option to buy 1,849 shares of Issuer common stock that vested on February 14, 2022. Read SEC document |
| August 07, 2025 Filed Aug 11, 2025 22:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Tax withholdingCommon Stock | 402 | $650.06 | $261,324.12 |
DisclosureSEC source: 0000874716-25-000129 · wk-form4_1754949616.xml · nonDerivative · entry 2 Emerson Andrew · CIK 0002058587 · EVP, CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,870.778 Read SEC document |
| August 07, 2025 Filed Aug 11, 2025 22:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 1,849 | $141.60 | $261,818.40 |
DisclosureSEC source: 0000874716-25-000129 · wk-form4_1754949616.xml · nonDerivative · entry 1 Emerson Andrew · CIK 0002058587 · EVP, CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,272.778 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes a total of 27.3420 shares purchased under the Issuer Employee Stock Purchase Plan on March 31, 2025 and June 30, 2025. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.